Exact Sciences (EXAS)
(Real Time Quote from BATS)
$59.41 USD
+0.62 (1.06%)
Updated Apr 26, 2024 01:28 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EXAS 59.41 +0.62(1.06%)
Will EXAS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXAS
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
Other News for EXAS
Exact Sciences Announces Board Member Retirement
Artisan Mid Cap Fund Q1 2024 Commentary
Baron Health Care Fund Q1 2024 Shareholder Letter
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Exact Sciences CFO's resume 'impressive,' says William Blair